Daré Bioscience is focused on transforming women’s health by advancing high-impact, first-in-category product candidates that have already demonstrated proof of concept. The company is driven by a mission to accelerate a diverse portfolio of novel therapies for women that expand treatment options, improve outcomes, and facilitate convenience. With clinical trials underway, their initial focus areas include contraception, fertility, and sexual and vaginal health.

Daré Bioscience, Inc.

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women.  

Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene®, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology.

Daré’s EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Daré is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra®, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer. 


The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Bill & Melinda Gates Foundation

Lincoln Park Capital Fund

We are excited to announce the commencement of our pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive.

The multi-center, single arm, non-comparative, pivotal Phase 3 clinical study of Ovaprene will evaluate the effectiveness, safety and usability of this unique contraceptive option. If approved by the FDA, Ovaprene would provide women in the U.S. with a hormone-free, self-administered, and monthly birth control method. #womenshealth

Learn more: https://bit.ly/47GRyMC

In honor of #WorldAIDSDay, we remember the lives lost to AIDS-related illnesses and advocate for health equity to eliminate disparities and barriers to testing, prevention, and care. Let’s unite to achieve health equity and support efforts to end HIV. 

Learn what you can do to support the movement: https://worldaidsday.org #RockTheRibbon

Today is #GivingTuesday – an opportunity to highlight and support organizations working to ensure women have access to the quality #healthcare and #innovation they want and deserve. Consider making a donation to the Center for Reproductive Rights or to one of the many organizations working tirelessly to improve the health and well-being of women and to advance health equity.

During this time of giving thanks, we express gratitude for the collective Daré team and their commitment to advancing innovation in women’s health. Their passion for boldly addressing therapeutic gaps and destigmatizing the conversation is making a difference in the quality of life of women every day. #TeamDaré

In honor of #womensentrepreneurshipday yesterday, we celebrate and support the many female entrepreneurs and leaders in the health and life sciences. To those who work boldly to break barriers in #womenshealth by addressing gaps, accelerating innovation, and destigmatizing the conversation, we recognize your tireless efforts to drive change. Women’s health is healthcare and women need, and deserve, more. 

#choosewomen #womenshealthmatters #womenhelpingwomen

We’re excited to announce the extension of our strategic partnership with Premier Research to accelerate the development of our novel women’s health programs. 

Premier Research is a global clinical research company with women’s health expertise that includes more than 100 clinical trials over the past five years, a network of thousands of women’s health sites, and a proven track record of working with multiple divisions of the US FDA. We look forward to continuing our collaboration with Premier, which aims to advance our reproductive health portfolio in a timely and capital-efficient manner. #womenshealth 

Learn more here: https://bit.ly/3sK1wxJ

COM:DAREBIOSCIENCE

Daré Bioscience

Last Close

3.60

26/07 20:00

Market Cap

27.97M

Beta: -

Volume Today

8.99K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

Metrics